Pfizer · NSE: PFIZER · BSE: 500680
Q4 FY24 results · Jan–Mar 2024
Pfizer reported revenue from operations of ₹546.63 crore (down 4.5% from Q4 FY23) and net profit of ₹178.86 crore (up 38.0% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a standalone basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 546.63 | 572.64 | −4.5% | 539.97 | +1.2% |
| Other income | 75.13 | 31.38 | +139.4% | 35.85 | +109.6% |
| Total income | 621.76 | 604.02 | +2.9% | 575.82 | +8.0% |
| Profit before tax | 243.86 | 164.72 | +48.0% | 175.94 | +38.6% |
| Net profit for the period | 178.86 | 129.65 | +38.0% | 129.98 | +37.6% |
| EPS, basic (₹) | 22.33 | 28.34 | not comparable | 27.12 | −17.7% |
| Net margin (%) | 32.7 | 22.6 | 24.1 |
Standalone
- Filed with BSE
- 18 May 2024, 11:22 IST
- Board meeting
- 17 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE